Local Applications of Myostatin-siRNA with Atelocollagen Increase Skeletal Muscle Mass and Recovery of Muscle Function

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kawakami, Emi ^a   Kawai, Nobuhiko ^a   Kinouchi, Nao ^a   Mori, Hiroyo ^a   Ohsawa, Yutaka ^b   Ishimaru, Naozumi ^a   Sunada, Yoshihide ^b   Noji, Sumihare ^a   Tanaka, Eiji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOGENIC FACTOR; ATELOCOLLAGEN; ATELOCOLLAGEN MYOSTATIN SMALL INTERFERING RNA COMPLEX; CAVEOLIN 3; MYOGENIC FACTOR; MYOSTATIN; NANOPARTICLE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ELECTROMYOGRAPHY; GENE EXPRESSION; GENE TARGETING; HISTOLOGY; MASSETER MUSCLE; MOUSE; MST GENE; MUSCLE CONTRACTION; MUSCLE FIBRIL; MUSCLE FUNCTION; MUSCLE GROWTH; MUSCLE MASS; MUSCULAR DYSTROPHY; NONHUMAN; REGULATOR GENE; SKELETAL MUSCLE; TELEMETRY; TRANSGENIC MOUSE; TREATMENT OUTCOME; UPREGULATION;

ANIMALS; COLLAGEN; ELECTROMYOGRAPHY; MASSETER MUSCLE; MICE; MICE, TRANSGENIC; MYOSTATIN; ORGAN SIZE; RNA, SMALL INTERFERING;

EID: 84878063536     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064719     Document Type: Article

References (39)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, et al. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
2. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
3. Lares MR, Rossi JJ, Ouellet DL, (2011) RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 28: 570-579.
4. Phalon C, Rao DD, Nemunaitis J, (2010) Potential use of RNA interference in cancer therapy. Expert Rev Mol Med 12: e26.
5. Akhtar S, Benter I, (2007) Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 59: 164-182.
6. Tagami T, Suzuki T, Matsunaga M, Nakamura K, Moriyoshi N, et al. (2012) Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm 422: 280-289.
7. Takeshita F, Minakuchi Y, Nagahara S, Honma K, Sasaki H, et al. (2005) Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 102: 12177-12182.
8. Takeshita F, Ochiya T, (2006) Therapeutic potential of RNA interference against cancer. Cancer Sci 97: 689-696.
9. Kinouchi N, Ohsawa Y, Ishimaru N, Ohuchi H, Sunada Y, et al. (2008) Atelocollagen-mediated local and systemic applications of myostatin-targeting siRNA increase skeletal muscle mass. Gene Ther 15: 1126-1130.
10. Kawakami E, Kinouchi N, Adachi T, Ohsawa Y, Ishimaru N, et al. (2011) Atelocollagen-mediated systemic applications of myostatin-targeting siRNA improve the muscular atrophy of caveolin-3-deficient mice. Dev Growth Differ 53: 48-54.
11. McPherron AC, Lawler AM, Lee SJ, (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387: 83-90.
12. Nishi M, Yasue A, Nishimatu S, Nohno T, Yamaoka T, et al. (2002) A missense mutant myostatin causes hyperplasia without hypertrophy in the mouse muscle. Biochem Biophys Res Commun 293: 247-251.
13. Lee SJ, McPherron AC, (2001) Regulation of myostatin activity and muscle growth. Proc Natl Acad Sci USA 98: 9306-9311.
14. Ohsawa Y, Hagiwara H, Nakatani M, Yasue A, Moriyama K, et al. (2006) Muscular atrophy of caveolin-3-deficient mice is rescued by myostatin inhibition. J Clin Invest 116: 2924-2934.
15. O'Brien KF, Kunkel LM, (2001) Dystrophin and muscular dystrophy: past, present, and future. Mol Genet Metab 74: 75-88.
16. Moxley RT III, Ashwal S, Pandya S, Connolly A, Florence J, et al. (2005) Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64: 13-20.
17. Bulfield G, Siller WG, Wight PA, Moore KJ, (1984) X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 81: 1189-1192.
18. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, et al. (2004) AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 10: 821-828.
19. Deconinck N, Dan B, (2007) Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 36: 1-7.
20. Cooper BJ, (1989) Animal models of Duchenne and Becker muscular dystrophy. Br Med Bull 45: 703-718.
21. Tinsley JM, Davies KE, (1993) Utrophin: a potential replacement for dystrophin? Neuromuscul Disord 3: 537-539.
22. Sunada Y, Ohi H, Hase A, Ohi H, Hosono T, et al. (2001) Transgenic mice expressing mutant caveolin-3 show severe myopathy associated with increased nNOS activity. Hum Mol Genet 10: 173-178.
23. Zhu X, Hadhazy M, Wehling M, Tidball JG, McNally EM, (2000) Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. FEBS Lett 474: 71-75.
24. Paul AC, Rosenthal N, (2002) Different modes of hypertrophy in skeletal muscle fibers. J Cell Biol 156: 751-760.
25. Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA, (1996) MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev 10: 1173-1183.
26. Magee TR, Artaza JN, Ferrini MG, Vernet D, Zuniga FI, et al. (2006) Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med 8: 1171-1181.
27. Emory AEH (1988) Duchenne Muscular Dystrophy. Oxford Univ. Press, 2nd, Oxford.
28. Yoshida Y, Marcus RL, Lastayo PC, (2012) Intramuscular adipose tissue and central activation in older adults. Muscle Nerve 46: 813-816.
29. Hu E, Tontonoz P, Spiegelman BM, (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPARγ and C/EBPα. Proc Natl Acad Sci USA 92: 9856-9860.
30. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, et al. (2002) C/EBPα induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 16: 22-26.
31. Bottinelli R, Canepari M, Pellegrino MA, Reggiani C, (1996) Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. J Physiol 495: 573-586.
32. Korfage JA, Koolstra JH, Langenbach GE, van Eijden TM, (2005) Fiber-type composition of the human jaw muscles-(part 1) origin and functional significance of fiber-type diversity. J Dent Res 84: 774-783.
33. Maughan RJ, Watson JS, Weir J, (1983) Strength and cross-sectional area of human skeletal muscle. J Physiol 338: 37-49.
34. Sano R, Tanaka E, Korfage JAM, Langenbach GEJ, Kawai N, et al. (2007) Heterogeneity of fiber characteristics in the rat masseter and digastric muscles. J Anat 211: 464-470.
35. Kawai N, Tanaka E, Langenbach GEJ, van Wessel T, Brugman P, et al. (2007) Daily jaw muscle activity in freely moving rats measured with radio-telemetry. Eur J Oral Sci 115: 15-20.
36. Langenbach GE, van Ruijven LJ, van Eijden TM, (2002) A telemetry system to chronically record muscle activity in middle-sized animals. J Neurosci Methods 114: 197-203.
37. Kawai N, Tanaka E, Langenbach GEJ, van Wessel T, Sano R, et al. (2008) Jaw muscle activity changes after the induction of osteoarthrosis in the temporomandibular joint by mechanical loading. J Orofac Pain 22: 153-162.
38. Kawai N, Sano R, Korfage JAM, Nakamura S, Kinouchi N, et al. (2010) Adaptation of rat jaw muscle fibers in postnatal development with a different food consistency: an immnohistochemical and EMG study. J Anat 216: 717-723.
39. van Wessel T, Langenbach GEJ, Korfage JAM, Brugman P, Kawai N, et al. (2005) Fiber type composition of rabbit jaw muscles is related to their daily activity. Eur J Neurosci 22: 2783-2791.